Gastroenterology organization states that around 15 to 25% people across the globe are gastrointestinal diseases and the therapeutic diagnosis reached $51.8 billion in 2016 to suffering Gastroesophageal Reflux diseases (GERD). European gastrointestinal Endoscopic market is expected to develop to over $4.4 Billion by 2020. The global market for $63.8 billion in 2021 at an annual growth rate 4.3% from 2016-2021.According to the worldwide expert in therapeutic gadget statistical surveying, North America lays on the 1st place in the market share, Europe Stands at 3rd most place in gastrointestinal therapeutics and pharmacology. As per the (Transparency Market Research) the drug class, acid neutralizers segment not led in the past, but is also expecting that would be a leading position in the coming years as all around the globe facing the Digestive disorders.
In terms of geographical regions, the Americas will account for about 55% of the total market shares by 2020 and will also be the major revenue contributor to the gastrointestinal therapeutics market throughout the provision period. The rising acceptance of biologics and the introduction of healthcare reforms by various countries in the region will be given enrichment to the market's growth prospects in the next four years.North America held 41% of the market in 2016. Europe has also been witnessing a healthy growth and is prophesied to continue being a fascinating region for gastrointestinal drugs in the market.
2018 Global Digestive Tract Stent Industry Report is a professional in-depth research report on world’s major regional market conditions of the Gastrintestinal stent market. Considering the major regions (North America, Europe, Asia) and the main countries (United States, Germany, Japan and China),"The exposure of biosimilars for considering inflammatory bowel diseases will also be a key growth for the market in Europe". However, Asia Pacific region is assuming that with maximum opportunities for growth in the coming years.The growing speculation and funding in the field of life science research and advanced therapies are rehabilitating the gastrointestinal diseases in developing nations such as China and India will fuel the growth of the Asia Pacific market.
Ten years from now the practice of gastroenterology will have a very different look and feel. Many doctors are trying to keep up with the pace of change in the structure of practices. Realignments and the decline of office-based private practice have been rapid and dramatic. We live in an era of health system empowerment and many physicians are struggling to adjust. Technological and therapeutic advances will also alter the landscape. Change in workflow, increase reliance on ancillary personnel such as physician assistants and medical assistants increase in scope as gastroenterologists devote more of their time to the procedure/technical based aspects of the specialty.